Patients should be aware that any weight loss associated with lipotropic programmes likely results from concurrent dietary restrictions and lifestyle changes rather than the injections themselves
WADA's rationale is that BPC-157 is a pharmacological substance not approved for human therapeutic use by any regulatory authority, and its tissue repair properties could provide a performance-enhancing benefit
Diabetologia 13 , 537544 (1977)
Technical description BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of a gastric protein that has been investigated in laboratory and preclinical research as a tool for studying cell-associated biological pathways
In a transected rat sciatic nerve model (Gjurasin et al., 2010, published in Regulatory Peptides), BPC-157 promoted functional nerve reconnection and accelerated axonal sprouting, with treated animals recovering motor function significantly faster than controls
However, it appears alongside peptides in the metabolic research space because its mechanism NNMT inhibition that preserves NAD+ and SAM pools intersects directly with the same cellular energy and epigenetic pathways that metabolic peptides target
